CareDx, Inc. (CDNA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 1:20 PM EDT
Company Participants
John Hanna – President, CEO & Director
Keith Kennedy – CFO & COO
Conference Call Participants
Elizabeth Koslosky – Goldman Sachs Group, Inc., Research Division
Presentation
Elizabeth Koslosky
Goldman Sachs Group, Inc., Research Division
All right. Good afternoon, everyone. I’m Evie Koslosky, Head of the Life Science Tools and Diagnostics team here at Goldman Sachs. I’m joined here today with CareDx. So thank you. Thank you for coming.
John Hanna
President, CEO & Director
Thanks so much for having us, Evie. We really appreciate it. I’m John Hanna. I’m the CEO here at CareDx, and I’m joined by Keith Kennedy, our COO and CFO.
Question-and-Answer Session
Elizabeth Koslosky
Goldman Sachs Group, Inc., Research Division
Great. So I guess just to kind of kick things off, your strategy since joining the company as CEO, John, has been to transform CareDx into a precision oncology leader. I guess, can you talk through the strategy, and what this means at a high level and key initiatives that you have in place to kind of achieve this precision medicine goal?
John Hanna
President, CEO & Director
Yes. Thanks so much. We really view CareDx as a precision diagnostics leader. And so when I got to the company, we did the typical thing as a management team to take a review of the entire business and understand like what are our strengths and weaknesses, and where do we really want to play, and where can we win as an organization. And in that strategic review, we identified that really the core competencies of the company are around building belief in molecular testing as the standard of care with health care providers, pulling through repeat testing in indications where patients are having tests ordered by a provider, over
Credit: Source link
